Registered Direct Offering
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing medicines for broad populations of cancer patients. The Company’s initial aim is to develop a universal-RAS therapy, an approach designed to include patients with solid tumors driven by any mutation in KRAS, NRAS or HRAS. Lead product candidate, IMM-1-104, a highly selective dual-MEK inhibitor, aims to achieve pan-KRAS/NRAS activity that selectively impacts cancer cells to a greater extent than healthy cells.